ACUPAN (nefopam) - Treatment of acute pain

Opinions on drugs - Posted on Mar 05 2025

Reason for request

First listing

Summary of opinion

Favourable opinion for reimbursement in the “Symptomatic treatment of acute painful conditions, especially post-operative pains”.

No clinical added value of the new form compared to the forms already available (ACUPAN 20 mg/2 mL solution for injection and its generics, and NEFOPAM PANPHARMA 30 mg film-coated tablets).

Clinical Benefit

Moderate

The Committee considers that the clinical benefit of ACUPAN 30 mg tablets (nefopam) is moderate in the MA indication.

Clinical Added Value

no clinical added value

This medicinal product is a range supplement that does not provide any clinical added value (CAV V) compared to the forms already listed (ACUPAN 20 mg/2 mL solution for injection and its generics, and NEFOPAM PANPHARMA 30 mg film-coated tablets).

The Committee highlights the fact that nefopam has no MA in chronic pain.